netFormulary North of Tyne and Gateshead Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
06.01.02.03  Expand sub section  Other antidiabetic drugs
Acarbose
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Alogliptin
(DPP4 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Alogliptin / metformin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Canagliflozin
(SGLT2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
  • Only approved for use in accordance with NICE guidance. 
 
Link  NICE TA315: Canagliflozin for type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dapagliflozin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
  • Only approved for use in accordance with NICE guidance. 
 
Link  NICE TA 418: Dapagliflozin in triple therapy for treating type 2 diabetes
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dulaglutide (Trulicity®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
  • 0.75mg and 1.5mg prefilled syringes
  • Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy. 
  • This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist
 
   
Empagliflozin
(SGLT-2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
  • Only approved for use in accordance with NICE guidance. 
 
Link  NICE TA336: Empagliflozin for type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Exenatide
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
  • 5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
  • 2mg once weekly pre-filled pen. Non-formulary (October 2017) Existing patients can continue to receive exenatide until reviewed by a specialist
  • Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
 
Link  EXENATIDE (Byetta®) - Information for Primary Care
Link  NICE TA248: Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
   
Linagliptin
(DPP4 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
 
   
Liraglutide (Victoza® )
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
  • Only approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance . 

 

 

 
Link  NICE NG28 - Type 2 diabetes in adults: management
Link  NICE TA203: Liraglutide for the treatment of type 2 diabetes mellitus (Replaced by NICE NG28)
   
Lixisenatide
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
 
   
Pioglitazone
(Thiazolidinedione)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Sitagliptin
(DPP4 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.   

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.  

Green

Drugs where prescribing by GPs is appropriate. Drugs not classified as Red, Amber or Green Plus (formerly blue in North of Tyne) are generally classified as ‘Green’ by default. The Green drugs listed here include those products normally initiated by hospital specialists where there was a need for discussion and debate as to the category in which they should be placed.  

netFormulary